What is Inhibrx Biosciences, Inc.'s D&A?

Inhibrx Biosciences, Inc. (INBX) reported D&A of $537K in Q1 2026.

How has Inhibrx Biosciences, Inc.'s D&A changed year-over-year?

Inhibrx Biosciences, Inc.'s D&A decreased by 20.4% year-over-year, from $675K to $537K.

What is the long-term trend for Inhibrx Biosciences, Inc.'s D&A?

Over 2 years (2023 to 2025), Inhibrx Biosciences, Inc.'s D&A has grown at a 44.4% compound annual growth rate (CAGR), from $1.19M to $2.48M.

Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

Inhibrx Biosciences, Inc. INBX D&A

D&A at other companies

PfizerPFE

$1.61B-0.3%

Rogers CorporationROG

$13.4M+6.3%

Nuvation BioNUVB

$536K+72.9%

ArriVent BioPharma, Inc.AVBP

-$559K+26.1%

ImmunomeIMNM

$603K-1.3%

Replimune GroupREPL

$800K-20.0%

Other financials

Income statement

See full

Revenue--100%

Operating income-$30.9M+27.9%

Net income-$33.4M+22.8%

EPS (diluted)-$2.15+23.2%

Balance sheet

See full

Cash & equivalents$161.7M-25.3%

Total debt$180.9M+69.8%

Total equity-$21.0M-122%

Total assets$184.0M-24.2%

Cash flow

See full

Operating cash flow-$38.0M-5.9%

CapEx--100%

Free cash flow-$38.0M-5.9%

Valuation

See full

Market cap$1.4B+546%

Enterprise value$1.42B+1,233%

P/S1,073.7×-280×

Profitability

See full

Operating margin-10,386.5%-5,025pp

Net margin-10,773.5%-878,492pp

FCF margin-9,986.5%-4,727pp

Returns & leverage

See full

Return on equity-197.8%-2,158pp

Debt / equity13.4×+13.3×

Current ratio6.5×+1.3×

Where this comes from

Reported directly by Inhibrx Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The official record: Inhibrx Biosciences, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Inhibrx Biosciences, Inc.'s d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Inhibrx Biosciences, Inc.'s D&A?: Inhibrx Biosciences, Inc. (INBX) reported D&A of $537K in Q1 2026.
How has Inhibrx Biosciences, Inc.'s D&A changed year-over-year?: Inhibrx Biosciences, Inc.'s D&A decreased by 20.4% year-over-year, from $675K to $537K.
What is the long-term trend for Inhibrx Biosciences, Inc.'s D&A?: Over 2 years (2023 to 2025), Inhibrx Biosciences, Inc.'s D&A has grown at a 44.4% compound annual growth rate (CAGR), from $1.19M to $2.48M.
What does D&A mean?: Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.